Can reduced active T3 availability contribute to low energy and weight fluctuations?

Active triiodothyronine (T3) is the primary thyroid hormone governing systemic metabolic rate and cellular energy homeostasis. Reduced availability of active T3 (free T3) is a recognized driver of clinical fatigue and metabolic deceleration, particularly during physiological transitions.

Clinical and metabolic impacts

• Energy depletion and fatigue: Decreased T3 availability directly lowers resting energy expenditure (REE) and down-regulates cellular energy processes. This state of relative tissue-level hypothyroidism can occur even when upstream markers like thyroid-stimulating hormone (TSH) remain within normal ranges. Impaired peripheral conversion of T4 to T3 (low T3 syndrome) is strongly associated with profound fatigue, mirroring symptoms seen in chronic fatigue syndrome.
• Weight fluctuations: Lowered active T3 reduces the metabolic threshold, facilitating weight gain and making weight management difficult. This metabolic adaptation is frequently triggered by chronic caloric deficits, illness, and age-dependent hormonal shifts, such as the menopause transition in women in their mid-50s.

Mitochondrial and molecular mechanisms

• Mitochondrial biogenesis: T3 binds to nuclear thyroid hormone receptors ($\text{TR}\alpha$ and $\text{TR}\beta$) to upregulate PGC-1$\alpha$, a master regulator that coactivates NRF-1/2 and TFAM to drive mitochondrial DNA replication. T3 also recruits AMPK pathways to clear damaged mitochondria through mitophagy.
• Metabolic uncoupling: T3 controls the resting metabolic rate by inducing uncoupling protein 3 (UCP3) in skeletal muscle and synergizing with noradrenergic signaling to upregulate uncoupling protein 1 (UCP1) in brown adipose tissue. These proteins facilitate a proton leak across the inner mitochondrial membrane, uncoupling oxidative phosphorylation to dissipate energy as heat.

Bottom line

• Reduced active T3 availability directly compromises mitochondrial biogenesis via PGC-1$\alpha$ and impairs energy expenditure via UCP1/UCP3 uncoupling, ultimately driving clinical fatigue and weight fluctuations.